# A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)

> **NCT01702857** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 100 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant
- **BIOLOGICAL:** Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant
- **OTHER:** Phosphate buffered saline
- **BIOLOGICAL:** 1 µg TDENV-PIV with Alum adjuvant
- **BIOLOGICAL:** 1 µg TDENV-PIV with AS01E adjuvant

## Key facts

- **NCT ID:** NCT01702857
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-03-23
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702857, "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01702857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*